NCT05065021 2024-01-17
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Phase 2 Unknown
Clinical Trials
66 trialsNCT03935256 2023-12-18
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
Phase 2 Unknown
NCT00997009 2023-11-14
MITO CERV 2
National Cancer Institute, Naples
Phase 2 Unknown
NCT03503786 2023-11-13
MITO END-3
National Cancer Institute, Naples
Phase 2 Unknown
NCT02584478 2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3 Unknown
NCT04938583 2023-10-17
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
CanariaBio Inc.
Phase 1/2 Unknown
NCT00411138 2023-10-11
PORTEC-3
Leiden University Medical Center
Phase 3 Unknown
NCT04201561 2023-06-26
SELENIUM
Seoul National University Hospital
Phase 3 Unknown
NCT00326456 2023-03-27
MITO-2: A Study Comparing 2 Chemotherapy Regimens (Carboplatin/Liposomal Doxorubicin vs Carboplatin/Paclitaxel) in Patients With Ovarian Cancer
National Cancer Institute, Naples
Phase 3 Unknown
NCT00660842 2023-03-24
MITO-7
National Cancer Institute, Naples
Phase 3 Unknown
NCT01706120 2023-03-24
MITO16/MANGO-2
National Cancer Institute, Naples
Phase 4 Unknown
NCT01802749 2023-03-24
MITO16MANGO2b
National Cancer Institute, Naples
Phase 3 Unknown
NCT03410784 2023-03-24
MITO28MaNGOov4
National Cancer Institute, Naples
Phase 2 Unknown
NCT05541146 2023-03-23
Intraperitoneal Chemotherapy in Gastric Cancer With Peritoneal Carcinomatosis
Instituto do Cancer do Estado de São Paulo
Phase 2 Unknown
NCT03321188 2023-02-06
Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients
University of Kansas Medical Center
Phase 2 Unknown
NCT05446883 2022-11-30
QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03794778 2022-07-18
Evaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
Women's Hospital School Of Medicine Zhejiang University
Phase 4 Unknown
NCT02639650 2022-06-03
Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor
Women's Hospital School Of Medicine Zhejiang University
Phase 3 Unknown
NCT05158062 2022-04-26
Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer
Saitama Medical University International Medical Center
Phase 2 Unknown
NCT03570437 2022-03-02
COPELIA
University of Manchester
Phase 2 Unknown
NCT01042522 2022-01-25
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
GOG Foundation
Phase 2 Unknown
NCT05145218 2021-12-08
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Unknown
NCT00942357 2021-10-19
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
GOG Foundation
Phase 3 Unknown
NCT04974944 2021-10-01
First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT00108745 2021-09-30
Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 3 Unknown
NCT00954174 2021-09-30
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 3 Unknown
NCT01366183 2021-09-30
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
GOG Foundation
Unknown
NCT04731038 2021-09-17
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
Phase 1 Unknown
NCT03462212 2021-08-27
MITO25
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Unknown
NCT04238988 2021-08-27
MITO CERV 3
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT04679064 2021-08-27
NItCHE-MITO33
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 3 Unknown
NCT04973904 2021-07-22
Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer
Peking Union Medical College Hospital
Phase 2 Unknown
NCT04072263 2021-04-01
OVACURE
Leiden University Medical Center
Phase 1/2 Unknown
NCT02822157 2021-01-29
CLIO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Unknown
NCT03912415 2020-09-18
FERMATA
Biocad
Phase 3 Unknown
NCT00652119 2020-08-19
Intraperitoneal Paclitaxel and Carboplatin With IV Avastin Therapy in Patients With Carcinomas of Mullerian Origin
Massachusetts General Hospital
Phase 1 Unknown
NCT04261465 2020-02-07
NUVOLA
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 2 Unknown
NCT03693248 2019-12-10
ROCOCO
Seoul National University Hospital
Phase 3 Unknown
NCT04000295 2019-10-08
Apatinib and Etoposide Capsule Versus Weekly Paclitaxel in Patients With Platinum Resistant Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Unknown
NCT03912402 2019-05-09
Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)
Biocad
Phase 2 Unknown
NCT01295502 2019-03-12
Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer
GOG Foundation
Phase 1 Unknown
NCT03818282 2019-02-26
OC-01
Huazhong University of Science and Technology
Phase 2 Unknown
NCT03763123 2018-12-04
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1 Unknown
NCT03539328 2018-05-29
MITO27
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT01650376 2018-03-23
Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer
Swedish Medical Center
Phase 1/2 Unknown
NCT02629718 2018-03-16
SYSGO-003
Sun Yat-sen University
Phase 3 Unknown
NCT03095001 2017-04-13
Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion
Chinese PLA General Hospital
Phase 2 Unknown
NCT02244502 2016-09-21
Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)
NovoCure Ltd.
Phase 1/2 Unknown
NCT02545010 2016-06-22
Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer
National University Hospital, Singapore
Phase 1 Unknown
NCT01755845 2016-04-28
Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients
Wenzhou Medical University
Phase 3 Unknown